18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
SH
Overseen BySteven H Lin, MD, PHD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
Research Team
SH
Steven H Lin, MD, PHD
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
Inclusion Criteria
I can sign and understand the consent form.
I am a woman able to have children and have a recent negative pregnancy test.
My esophageal cancer has not spread far from its original site.
See 1 more
Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive 18F-FSPG IV and undergo PET/CT scans during standard of care radiation therapy
3 weeks
2 visits (in-person)
Follow-up
Participants are monitored for safety and effectiveness after treatment
48 weeks
Treatment Details
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ObservationalExperimental Treatment1 Intervention
Patients receive 18F-FSPG IV and undergo a PET/CT scan. During week 3 of standard of care radiation therapy, patients receive 18F-FSPG and undergo a second PET/CT scan on study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Trials
3,107
Recruited
1,813,000+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.